$5.42 0.4 7.1%
Last Trade - 7:05pm
| Market Cap | £427.6m |
| Enterprise Value | £336.6m |
| Revenue | £2.90m |
| Position in Universe | 3314th / 6852 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 9.30 | 8.90 | 5.84 | 4.16 | 9.86 | 4.05 | 26.4 | 89.5 | -15.3% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | March 14, 1969 |
| Public Since | March 17, 1980 |
| No. of Shareholders: | 6,497 |
| No. of Employees: | 28 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Capital Market |
| Shares in Issue | 117,766,672 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 385 Oyster Point Boulevard Suite 9A, SOUTH SAN FRANCISCO, 94080, United States |
| Web | https://vaxart.com/ |
| Phone | +1 650 5503500 |
| Contact | () |
| Auditors | KPMG LLP |
As of 7:05pm, shares in Vaxart Inc are trading at $5.42, giving the company a market capitalisation of £427.6m. This share price information is delayed by 15 minutes.
Shares in Vaxart Inc are currently trading at $5.42 and the price has moved by 0.114k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Vaxart Inc price has moved by 40.34% over the past year.
Of the analysts with advisory recommendations for Vaxart Inc, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Vaxart Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Vaxart Inc is scheduled to issue upcoming financial results on the following dates:
Vaxart Inc does not currently pay a dividend.
Vaxart Inc does not currently pay a dividend.
Vaxart Inc does not currently pay a dividend.
To buy shares in Vaxart Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Vaxart Inc are currently trading at $5.42, giving the company a market capitalisation of £427.6m.
Here are the trading details for Vaxart Inc:
Based on an overall assessment of its quality, value and momentum, Vaxart Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Vaxart Inc are currently priced at $5.42. At that level they are trading at 0.163% discount to the analyst consensus target price of 0.00.
Analysts covering Vaxart Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.407 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vaxart Inc. Over the past six months, the relative strength of its shares against the market has been -22.72%. At the current price of $5.42, shares in Vaxart Inc are trading at -32.66% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Vaxart Inc.
Vaxart Inc's management team is headed by:
Here are the top five shareholders of Vaxart Inc based on the size of their shareholding:
